wee-1.1 Antibody

Definition and Function of Wee1 Antibodies

Wee1 antibodies are designed to bind specifically to the Wee1 protein kinase, which functions as a negative regulator of mitotic entry. These antibodies are used in laboratory techniques such as Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), and ELISA to:

• Detect Wee1 expression levels in nuclear compartments .

• Study post-translational modifications, such as phosphorylation, that regulate Wee1 activity .

• Analyze Wee1’s interaction with CDK1 and other cell cycle proteins .

Wee1 antibodies are available as monoclonal (e.g., clone 5B6 , B-11 ) or polyclonal (e.g., Novus NBP1-33506 ) reagents, each with distinct epitope specificities and species reactivity.

Role in Cell Cycle Regulation

Wee1 antibodies have elucidated the kinase’s role in:

• G2/M Checkpoint Control: Wee1 phosphorylates CDK1 on Tyr15, inhibiting its activity until DNA replication is complete . Antibody depletion experiments confirm Wee1 as the primary kinase responsible for this modification .

• M Phase Suppression: Wee1 activity is strongly reduced during mitosis, enabling CDK1 activation and mitotic progression .

Applications in Experimental Research

Therapeutic and Diagnostic Potential

While not directly therapeutic, Wee1 antibodies aid in studying the kinase’s role in diseases like cancer. Overexpression of Wee1 is associated with genomic instability, making it a candidate for targeted therapies .

Table 1: Comparative Analysis of Wee1 Antibodies

Table 2: Dilution Recommendations for Common Applications

Challenges and Future Directions

• Specificity Concerns: Cross-reactivity with homologous kinases (e.g., Myt1) may require optimization .

• Post-Translational Modifications: Detection of phosphorylated Wee1 isoforms remains challenging due to epitope masking .

• Therapeutic Antibodies: Development of anti-Wee1 antibodies for targeted cancer therapies is an emerging area of research.